In this study, vx-765 treatment enhanced the expression levels of TIMP-1 and TIMP-2 but reduced the expression levels of MMP-1, MMP-2, MMP-3, and MMP-9 proteins after cerebral infarction. Here, MMP9 is linked to cerebral infarction.